NovaBridge Biosciences
givastomig
HER2-negative metastatic gastric cancer
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews givastomig for HER2-negative metastatic gastric cancer around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 6-K
verified 12h ago
“EX-99.1 2 nbp-ex99_1.htm EX-99.1 Exhibit 99.1 NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer”